374104-63-9

Basic information

• Product Name: 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE
• Synonyms: THIENO[2,3-D]PYRIMIDINE, 4-CHLORO-5-(4-METHYLPHENYL)-;OTAVA-BB BB7012780012;AURORA 20403;BUTTPARK 82\18-64;4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE;4-CHLORO-5-(4-METHYLPENYL)THIENO[2,3-D]PYRIMIDINE;4-CHLORO-5-(4-METHYLPHENYL)THIENO[2,3-D]PYRIMIDINE
• CAS NO: 374104-63-9
• Molecular Formula: C13H9ClN2S
• Molecular Weight: 260.74
• Mol File: 374104-63-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 425.6 °C at 760 mmHg
• Flash Point: 211.2 °C
• Appearance: /
• Density: 1.351 g/cm³
• Vapor Pressure: 4.69E-07mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE(374104-63-9)
• EPA Substance Registry System: 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE(374104-63-9)

Safety Data

• Hazardous Substances Data: 374104-63-9(Hazardous Substances Data)

Usage

General Description

4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE is a chemical compound with the molecular formula C13H9ClN2S. It is a thiophene derivative with a chloro and p-tolyl group attached to the pyrimidine ring. 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical compounds. It has potential applications in the development of anti-cancer, anti-inflammatory, and anti-bacterial drugs. Additionally, it has been studied for its potential use as a herbicide and pesticide. 4-CHLORO-5-P-TOLYL-THIENO[2,3-D]PYRIMIDINE is of interest to researchers and chemists due to its unique structural features and potential pharmacological activities.

InChI:InChI=1/C13H9ClN2S/c1-8-2-4-9(5-3-8)10-6-17-13-11(10)12(14)15-7-16-13/h2-7H,1H3

Upstream product

• 14505-28-3 ethyl 2?cyano?3?p?tolylbut?2?enoate 
• 15854-08-7 ethyl 2-amino-4-(4-methylphenyl)thiophene-3-carboxylate 
• 17509-21-6 5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 122-00-9 para-methylacetophenone 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3′,4′,5′-trimethoxyanilino)thieno[3,2-d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3′,4′,5′-trimethoxyanilino)-6-(p-tolyl)thieno[3,2-d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.

Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines

An extension of our previous research work has resulted in a number of new ATP-competitive CK2 inhibitors that have been identified among 4-aminothieno[2,3-d]pyrimidine derivatives. The most active compounds obtained in the course of the research are 3-(5-p-tolyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5e (NHTP23, IC50 = 0.01 μM), 3-(5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5g (NHTP25, IC50 = 0.065 μM) and 3-(6-methyl-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5n (NHTP33, IC50 = 0.008 μM). Structure-activity relationships of the tested 4-aminothieno[2,3-d]pyrimidine derivatives have been studied and their binding mode with ATP-acceptor site of CK2 has been proposed. A negative effect of intramolecular hydrogen bonding in the compounds' structure is discussed.

SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS

The invention discloses tachykinin receptor antagonists. The tachykinin family of receptors comprising the neurokinins substance P (SP), neurokinin A, and neurokinin B and related neuropeptides that are widely distributed in the peripheral and central ner